Greenwich LifeSciences, Inc.
GLSIAnalyst Consensus
Price Target Trend
Rating Trend
Recent Price Targets
| Date | Firm | Analyst | Target | Price Then | Source |
|---|---|---|---|---|---|
| Dec 30, 2025 | H.C. Wainwright | $50.00(+102%) | $24.78 | TheFly |
Recent Rating Actions
| Firm | Action | Rating | Date |
|---|---|---|---|
| HC Wainwright & Co. | maintain | Buy | Jul 21, 2026 |
| HC Wainwright & Co. | maintain | Buy | Dec 30, 2025 |
| HC Wainwright & Co. | maintain | Buy | Apr 21, 2025 |
| HC Wainwright & Co. | maintain | Buy | Feb 11, 2025 |
| HC Wainwright & Co. | maintain | Buy | Aug 23, 2024 |
| HC Wainwright & Co. | maintain | Buy | May 22, 2024 |
| HC Wainwright & Co. | maintain | Buy | Feb 28, 2024 |
| HC Wainwright & Co. | maintain | Buy | Feb 20, 2024 |
| HC Wainwright & Co. | maintain | Buy | Apr 10, 2023 |
| HC Wainwright & Co. | maintain | Buy | Sep 1, 2021 |
| Aegis Capital | maintain | Buy | Jan 27, 2021 |
| Aegis Capital | maintain | Buy | Jan 26, 2021 |
Earnings History
Next report: Nov 13, 2026 · EPS est. $-0.30| Report Date | EPS Actual | EPS Est. | Revenue Actual | Revenue Est. |
|---|---|---|---|---|
| Aug 11, 2026 | $-0.27 | $-0.33 | — | — |
| Jun 3, 2026 | $-0.39 | $-0.33 | — | — |
| Mar 31, 2026 | $-0.32 | $-0.32 | — | — |
| Nov 14, 2025 | $-0.30 | $-0.30 | — | — |
| Aug 14, 2025 | $-0.30 | $-0.24 | — | — |
| May 20, 2025 | $-0.25 | $-0.24 | — | — |
| Apr 15, 2025 | $-0.61 | $-0.21 | $3.6K | — |
| Nov 14, 2024 | $-0.20 | $-0.21 | — | — |
News
Greenwich LifeSciences, Inc. (NASDAQ: GLSI - Get Free Report)'s stock price fell 2.1% during mid-day trading on Friday. The stock traded as low as $16.60 and last traded at $16.98. Approximately 175,415 shares traded hands during mid-day trading, an increase of 57% from the average session volume of 111,705 shares. The stock had previously closed at
Certain stocks are such poor bets that they are likely to lose ground even in bull markets.
STAFFORD, Texas, Aug. 10, 2026 (GLOBE NEWSWIRE) -- Greenwich LifeSciences, Inc. (Nasdaq: GLSI) (the "Company"), a clinical-stage biopharmaceutical company focused on its Phase III clinical trial, FLAMINGO-01, which is evaluating Fast Track designated GLSI-100, an immunotherapy to prevent breast cancer recurrences, today announced that its Board of Directors has extended the lock-up of the shares owned by the Company's directors, officers, and existing pre-IPO investors to January 31, 2027 which …